|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-2.86/-2.69
|
企業價值
2.60B
|
資產負債 |
每股賬面淨值
12.72
|
現金流量 |
現金流量率
--
|
損益表 |
收益
6.88M
|
每股收益
0.07
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2024/05/15 23:29 EDT
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527. |